Type | Public company |
---|---|
Traded as | NASDAQ: GNVC |
Industry | Pharmaceuticals |
Headquarters | Gaithersburg, Maryland, United States |
Key people | Paul H. Fischer, President and CEO Douglas J. Swirsky, Senior Vice President and Chief Financial Officer |
Products | TNFeradeTM Phase III |
Revenue | $13.9 million (2009) |
Net income | $18.4 million (2009) |
Employees | 85 |
Website | www.genvec.com |
GenVec, Inc. is a biopharmaceutical company developing pharmaceuticals and vaccines based on novel biotechnology such as targeted delivery systems. The company has a number of drugs currently in various phases of clinical trials. Its lead product candidate is TNFerade, being developed for the treatment of solid tumors. The company has been contracted by the United States Department of Homeland Security to develop a vaccine for foot-and-mouth disease.[1]
TNFerade (the Company's lead product candidate) failed a phase III trial for pancreatic cancer. There was an 8% reduction in risk of death but it was not statistically significant.[2] TNFerade is “an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNFα), an immune system protein, for direct injection into tumors”.[2]